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Types of second primary cancers influence
survival in chronic lymphocytic and hairy
cell leukemia patients
Guoqiao Zheng 1,2, Subhayan Chattopadhyay 1,2, Amit Sud 1,3, Kristina Sundquist4,5,6, Jan Sundquist4,5,6,
Asta Försti1,4, Richard S. Houlston 3,7, Akseli Hemminki8,9 and Kari Hemminki1,4
Second primary cancers (SPCs) are becoming more
common as the survival in cancer is improving, and they
are of main concern in cancers of good survival because
they may cause early mortality. Here we want to test the
hypothesis that the type of SPC is critical for survival and
we further posit that the survival time can be predicted
from the fatality of these cancers as first primary cancers.
We test the hypotheses on two leukemias with good
survival, the common chronic lymphocytic leukemia
(CLL) and the rare hairy cell leukemia (HCL). In the
comparison of survival rates we use relative survival to
avoid biases in the definition of the cause of death.
CLL is characterized by the gradual accumulation of
small phenotypically mature malignant B lymphocytes in
the blood, bone marrow, and lymph nodes1. CLL may be
preceded by monoclonal B-cell lymphocytosis, which
evolves to CLL through genetic changes including somatic
mutations and chromosomal aberrations1. Many patients
are diagnosed at an asymptomatic stage and may not
initially require treatment. Management of symptomatic
patients includes chemotherapy with alkylating agents
and purine analogs, combination of chemotherapy and
immunotherapy, and drugs that target key signaling
pathways1,2. Survival rates for patients with CLL have
continuously improved mainly due to more efficient
treatment2,3. Increased survival rates increase the like-
lihood of SPCs, which may potentially interfere with
survival. Elevated risks for SPC have been reported in
patients with CLL, including non-melanoma skin cancer,
melanoma, sarcoma, and lung, renal, and prostate can-
cers4,5. It was reported that CLL patients with second
malignancies have a worse relative survival than non-CLL
patients with the same second malignancies6,7.
HCL is a B-cell disease with common somatic BRAF
mutations. Many patients have an indolent course and no
therapies are required8. Therapies were developed in 1990
based on purine analogs, which achieved good response
rates, and more recently targeted treatments have become
available including inhibition of the mutated BRAF
kinase8. Since 1990, relative survival has been close to the
background population among patients diagnosed before
the age of 60 years and has now improved to ~90% even
among elderly people8. Increased risks of SPCs in HCL
patients have been reported for Hodgkin and non-
Hodgkin lymphoma (NHL) and for thyroid cancer9,10.
We used data from the Swedish Cancer Registry to
assess survival in CLL and HCL with and without SPCs. In
addition, we grouped SPCs into three ‘prognostic groups’
based on 5-year relative survival of these cancers as first
primary cancer11,12: ‘good survival’ (relative survival >
60%) included cancers in the lip, larynx, anus, breast,
cervix, endometrium, prostate, testis, male genitals, kid-
ney, bladder, melanoma, skin (squamous cell, SCC), eye,
thyroid gland and endocrine, and Hodgkin lymphoma;
‘moderate survival’ (40–60%) included cancers in the
remaining upper aerodigestive tract, salivary glands, small
intestine, colorectum, female genitals, bone and con-
nective tissue, and NHL and ‘poor survival’ (<40%)
included cancers in the stomach, esophagus, liver, pan-
creas, lung, ovary and nervous system, and myeloma.
Relative survival was calculated by using the observed
survival in the patient cohort divided by the expected
survival obtained from the general cancer-free population
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(can be identified from the nation-wide cancer registry),
matched on age, sex, calendar period, county, and socio-
economic status. The expected survival was calculated
with the Ederer II method13. The standard error of the
observed survival was estimated by Greenwood’s for-
mula14. Patients diagnosed between 1991 and 2015 were
included in the study. Relative survival in adult patients
(>20 years), with and without SPC, was measured from
the time of diagnosis until death, immigration or 2015,
whichever came first. Multivariable Cox proportional
hazard regression model adjusting for sex, age at and
calendar year of first cancer diagnosis and socioeconomic
status was applied to assess hazard ratios (HRs) among
patients with SPC in different prognostic groups com-
pared to patients without SPC. In this model, the diag-
nosis of SPC was treated as a time-dependent variable in
order to avoid the immortal time bias15. Trend test was
performed by considering patients without any SPC, with
SPC of good, moderate, and poor prognosis as continuous
variable. All statistical analyses were performed in SAS
(version 9.4) and R software. The study was approved by
the ethical committee of the University of Lund.
Among 9338 CLL patients, a total of 1571 were diag-
nosed with SPC (16.8%) after a median (interquartile,
1–7) follow-up time of 4 years; 5639 deaths were recorded
and of these 1122 (19.9%) were in patients diagnosed with
a SPC. Among 718 HCL patients, a total of 119 were
diagnosed with SPC (16.6%) after a median (interquartile,
2–11) follow-up time of 7 years; of 234 HCL deaths, 57
(24.4%) were recorded in patients with SPC. For CLL
patients with second cancer of poor prognosis, the two
main SPCs were lung and brain cancers, for those with
moderate prognosis, they were NHL and colorectal can-
cer, and for those with good prognosis, they were skin
(squamous cell) and prostate cancers. In HCL patients
with second cancer, the two main SPCs were the same as
with CLL in three groups of different prognosis. Corre-
sponding case numbers, relative survival and 95% con-
fidence intervals (CIs) for CLL are detailed in
Supplementary Table 1.
Figure 1 shows relative survival for CLL and HCL, with
and without SPC, and in patients with SPC in the three
prognostic groups. For CLL, survival was significantly
better (non-overlapping 95%CIs) for patients with SPC
compared to those without SPC in the first year and years
2–5 after diagnosis (Fig. 1a, and Supplementary Table 1).
The survival rate was reversed in subsequent years but
was not significant. For HCL, the data between patients
with and without SPC were essentially similar: in year 1,
patients with SPC had significantly better survival than
those without SPC but survival was reversed at sub-
sequent periods, yet the differences were not significant
(Fig. 1b, Supplementary Table 1). CLL patients in the
good prognostic group showed excellent survival during
the first years but with time the rate equalized with that of
moderate prognosis (Fig. 1c). In the poor prognostic
group, survival was lower at all follow-up times and the
rates differed significantly from patients without SPC in
follow-up times after year 1. For HCL the survival of good
and moderate prognosis patients did not differ but those
for poor prognosis were modestly suppressed (significant
for years 7–16 years compared to patients without SPC).
Patients had to survive some time to be diagnosed with
SPC, which is a condition for immortality bias. To better
understand the effect of different prognostic groups on
the survival in SPC, a time-dependent analysis was
necessary to avoid the bias. Multivariable Cox propor-
tional hazard regression was performed by treating SPC
diagnosis as time-dependent variable (Table 1). CLL
patients with diagnosis of SPC of good prognosis experi-
enced worse survival compared to those without any SPC
diagnosis (HR= 1.76, 95%CI: 1.61–1.92). Patients with
SPC of moderate (HR= 2.18, 1.76–2.70) and poor prog-
nosis (HR= 5.83, 4.83–7.03) survived even worse. The
trend test for HRs was highly significant (P-trend= 2 ×
10–16). For HCL, the HRs for patients with SPCs of good,
moderate, and poor prognosis were, respectively, 1.69
(1.11–2.57), 2.15 (0.92, 5.02), and 13.34 (4.92–36.33) and
the trends were also significant (P-trend= 5 × 10−6).
The data shows that even for cancers with relatively
good overall survival, those with SPC are a subgroup for
whom survival may essentially deviate from patients
without SPC and who may often be forgotten in prog-
nostic evaluations. SPCs are a challenging issue con-
cerning cancer survival and attempts to increase patient
outcome cannot disregard the effect of SPCs. We tested,
for the first time, the hypothesis that survival in SPCs
would follow the survival experience known for first
primary cancers. The hypothesis appeared to be correct
and the trend tests between prognostic groups were
highly significant, especially for CLL with large case
numbers. Patients with SPC presented good survival in
the early stage of follow-up time which is known as
immortal time but experienced poor survival after diag-
nosis of SPC. This pattern of survival may indicate that
some active drugs have led to better outcomes early but
also caused mutations that subsequently lead to second
malignancies.
Early mortality in CLL and HCL may be caused by
severe infections. If the patient dies, SPCs may remain
underreported. Another reason for underreporting of
SPCs could be less vigilant diagnostic procedures in ill or
frail patients16. Such underreporting may be a compli-
cation in survival studies thus masking the influence of
SPCs but can be detected in the analysis of follow-up
trends.
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Table 1 Hazard ratio in patients diagnosed with SPC of good, moderate and poor prognosis compared to those without
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Years since diagnosis SPC of good prognosis SPC of moderate
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SPC of poor prognosis P-trend
N HR (95% CI) N HR (95% CI) N HR (95% CI)
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HCL 31 1.69 (1.11–2.57) 11 2.15 (0.92–5.02) 9 13.34 (4.92–36.33) 5 × 10−6
Diagnosis of second cancer of unknown primary was not considered in any prognostic groups
Fig. 1 Relative survival in CLL and HCL patients according to diagnosis of SPC. Relative survival stratified by period (with 95% confidence
interval) are shown for patients with and without SPC (a for CLL and b for HCL) as well as for patients with SPC of the good, morderate and poor
prognosis (c for CLL and d for HCL). SPC second primary cancer, CLL chronic lymphocytic leukemia, HCL hairy cell leukemia
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